Tag

#Global Pharmaceutical Market

Explore articles tagged with Global Pharmaceutical Market

Active Filters:
Tag: Global Pharmaceutical Market
Clear All
Licensed in Germany, Ready for Europe
Business & Growth

Licensed in Germany, Ready for Europe

HRV Pharma's acquisition of Germany-based Phatebo GmbH provides an established entry into the European pharmaceutical market. With German pharmaceutical wholesale authorisation, good distribution practice systems and an existing global customer base, the acquisition supports HRV's expansion into finished formulations while strengthening its international presence.

A New Chapter in Europe
Business & Growth

A New Chapter in Europe

HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.

Two Layers, One Value Chain
Business & Growth

Two Layers, One Value Chain

HRV Pharma is expanding across two layers of the pharmaceutical value chain through its acquisition of Phatebo GmbH. The combination brings together HRV's global API partner network and Phatebo's licensed European clinical trial supply and pharmaceutical distribution capabilities, while retaining the asset-light business model.

Into Clinical Trial Supply
Business & Growth

Into Clinical Trial Supply

HRV Pharma has expanded beyond APIs into clinical trial supply through its acquisition of Germany-based Phatebo. The company sources comparator, investigational and ancillary medicines for pharmaceutical companies and CROs worldwide, bringing HRV into a segment where reliability, traceability and timely delivery are essential.

A Foray Into European Markets
Business & Growth

A Foray Into European Markets

HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.

What Indian Pharma Is Really Buying
Business & Growth

What Indian Pharma Is Really Buying

Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.